Form 4 for ARWR ARROWHEAD PHARMACEUTICALS, INC.
Accepted 2022-07-12 00:00:00 ET · period of report 2022-07-08 · accession 0001209191-22-041979 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-07-12 | 2022-07-08 | ARWR | Anzalone Christopher Richard | CEO, Dir | D - Sale to Iss | $0.00 | -551.2K | 3.51M | -14% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-07-08 | D | D | 551,197 | $0.00 | 3,508,938 | D | — | — | (F1) Modification of previously granted award from 800,000 to 248,803. (F2) Includes a total of 1,649,282 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole. |